Expert Insights

Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.

A study presented at the AACR Annual Meeting demonstrates that spatial localization within the MCL tumor affects the expression of CD163-positive macrophages and identifies possible targetable markers.

Vivek Subbiah, MD, University of Texas, shares updates of pemigatinib in the upcoming FIGHT-302 study and highlights how an FDA approval will benefit patients with CCA harboring an FGFR2 mutation.

Susan Fineberg, MD, overviews EZH2 expression in the neoadjuvant setting to predict metastatic recurrence for patients with TNBC.

Christian Buske, MD, overviews a phase 3 study on the long-term safety and efficacy of CT-P10, a rituximab biosimilar, in patients with untreated advanced FL.

Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.

Vivek Subbiah, MD, University of Texas, overviews the FIGHT-101 trial on pemigatinib, a selective FGFR 1-3 inhibitor, which targets mutations across a variety of tumor types.

Van Morris, MD, reviews emerging targeted therapies for patients with metastatic colorectal cancer.

Vivian Strong, MD, discusses the need of surgeons working more closely with medical oncologists, GI experts, and basic scientists in order to push novel approaches forward for gastric cancer treatment.